Chemotherapy plus immunotherapy after surgery for stomach or bowel cancer with genetic markers
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (tislelizumab) after surgery can help prevent your cancer from coming back. It's especially for people whose tumors have certain genetic features that may make them more responsive to immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old, of any gender.
- Your tumor must have certain genetic markers (dMMR/MSI-H or POLE/POLD1 mutations) confirmed by a lab test.
- You have had complete surgery to remove your stomach, esophagus-stomach area, or bowel cancer, with no visible cancer left behind.
- Your cancer must be at a stage that is not advanced or spread to other organs.
- You must be in generally good health, with normal blood counts, liver, kidney, and heart function.
- You have not had chemotherapy, radiation, or hormone therapy for this cancer before surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination (tislelizumab plus apatinib and chemotherapy) before surgery for certain advanced stomach cancers, compared with the standard chemotherapy plus S1. The goal is to shrink the tumor and improve outcomes before and around surgery.
This trial tests adding an immunotherapy drug (tislelizumab) to standard chemotherapy (FLOT) before surgery for people with stomach or esophagus cancer that can be removed but hasn't spread. The goal is to see if this combination is safe and works better than chemotherapy alone.
This Phase 2 trial studies giving tislelizumab (an immune therapy) together with pre-surgery chemoradiation for locally advanced stomach or GEJ (esophagus-stomach junction) adenocarcinoma. It compares this approach to the standard treatment (chemoradiation plus surgery) to see if it improves outcomes.
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy after surgery can help prevent stage III stomach or gastroesophageal junction cancer from coming back. You may qualify if you had D2 surgery and your tumor tested positive for PD-L1.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests whether adding the immunotherapy drug Sintilimab to standard chemotherapy after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. It's for people with high-risk or advanced stage cancer that has a specific genetic feature (dMMR or MSI-H).
Hear when a new Gastric trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.